CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06264921
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:15.543027+00:00
Published At: 2025-09-25T00:00:00+00:00
Record Updated At: 2025-09-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Solid Tumor", "Solid Tumor, Adult", "Advanced Solid Tumor", "Metastatic Tumor", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Metastatic Ovarian Carcinoma", "Endometrial Cancer", "Endometrial Neoplasms", "Endometrial Diseases", "Metastatic Endometrial Cancer", "Metastatic Endometrial Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Ovarian Carcinoma", "Gastric Cancer", "Advanced Gastric Carcinoma", "Metastatic Gastric Cancer", "Metastatic Gastric Carcinoma", "Small-cell Lung Cancer", "Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Carcinoma", "CCNE1 Amplification", "Hormone Receptor Negative Breast Carcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Progesterone-receptor-positive Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-25"
protocolSection.identificationModule.nctId: "NCT06264921"
protocolSection.identificationModule.officialTitle: "A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Study condition terms

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.